Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma

Gastroenterology Clinics of North America

Volumn 44, Issue 2, 2015, Pages 203-231

  Runge, Thomas M ^a   Abrams, Julian A ^b   Shaheen, Nicholas J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Barrett's esophagus; Epithelium; Esophageal adenocarcinoma; Gastroesophageal reflux disease

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P53; PROTON PUMP INHIBITOR;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; BARRETT ESOPHAGUS; CANCER RISK; DISEASE ASSOCIATION; DISEASE COURSE; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS; ETHNIC DIFFERENCE; GASTROESOPHAGEAL REFLUX; GENETIC DISORDER; HELICOBACTER PYLORI; HUMAN; INCIDENCE; NONHUMAN; OBESITY; PREVALENCE; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SMOKING; SYSTEMATIC REVIEW (TOPIC); ADENOCARCINOMA; AGE; DRINKING BEHAVIOR; ESOPHAGEAL NEOPLASMS; ETHNOLOGY; HELICOBACTER INFECTIONS; PATHOLOGY; PRECANCEROUS CONDITIONS;

ADENOCARCINOMA; AGE FACTORS; ALCOHOL DRINKING; BARRETT ESOPHAGUS; BIOMARKERS; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; OBESITY; PRECANCEROUS CONDITIONS; PREVALENCE; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 84929961783     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.02.001     Document Type: Review

References (162)

1. Spechler S.J. Barrett's esophagus and esophageal adenocarcinoma: pathogenesis, diagnosis, and therapy. Med Clin North Am 2002, 86(6):1423-1445. vii.
2. Shaheen N., Ransohoff D.F. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002, 287(15):1972-1981.
3. Blot W.J. Esophageal cancer trends and risk factors. Semin Oncol 1994, 21(4):403-410.
4. Daly J.M., Karnell L.H., Menck H.R. National Cancer Data Base report on esophageal carcinoma. Cancer 1996, 78(8):1820-1828.
5. Hesketh P.J., Clapp R.W., Doos W.G., et al. The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989, 64(2):526-530.
6. Cameron A.J., Ott B.J., Payne W.S. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. NEngl J Med 1985, 313(14):857-859.
7. Shaheen N.J., Richter J.E. Barrett's oesophagus. Lancet 2009, 373(9666):850-861.
8. Lund O., Kimose H.H., Aagaard M.T., et al. Risk stratification and long-term results after surgical treatment of carcinomas of the thoracic esophagus and cardia. A 25-year retrospective study. JThorac Cardiovasc Surg 1990, 99(2):200-209.
9. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
10. Hvid-Jensen F., Pedersen L., Drewes A.M., et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. NEngl J Med 2011, 365(15):1375-1383.
11. Bhat S., Coleman H.G., Yousef F., et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. JNatl Cancer Inst 2011, 103(13):1049-1057.
12. Cameron A.J., Zinsmeister A.R., Ballard D.J., et al. Prevalence of columnar-lined (Barrett's) esophagus. Gastroenterology 1990, 99(4):918-922.
13. Ronkainen J., Aro P., Storskrubb T., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005, 129(6):1825-1831.
14. Rex D.K., Cummings O.W., Shaw M., et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003, 125(6):1670-1677.
15. Zagari R.M., Fuccio L., Wallander M.A., et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008, 57(10):1354-1359.
16. Westhoff B., Brotze S., Weston A., et al. The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 2005, 61(2):226-231.
17. Conio M., Cameron A.J., Romero Y., et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001, 48(3):304-309.
18. Coleman H.G., Bhat S., Murray L.J., et al. Increasing incidence of Barrett's oesophagus: a population-based study. Eur J Epidemiol 2011, 26(9):739-745.
19. van Soest E.M., Dieleman J.P., Siersema P.D., et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005, 54(8):1062-1066.
20. Cameron A.J., Lomboy C.T. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992, 103:1241-1245.
21. Wong A., Fitzgerald R.C. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005, 3(1):1-10.
22. van Blankenstein M., Looman C.W., Johnston B.J., et al. Age and sex distribution of the prevalence of Barrett's esophagus found in a primary referral endoscopy center. Am J Gastroenterol 2005, 100(3):568-576.
23. Kramer J.R., Fischbach L.A., Richardson P., et al. Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol 2013, 11(4):373-381.e1.
24. Ford A.C., Forman D., Reynolds P.D., et al. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 2005, 162(5):454-460.
25. Abrams J.A., Fields S., Lightdale C.J., et al. Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol 2008, 6(1):30-34.
26. Cameron A.J., Lagergren J., Henriksson C., et al. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002, 122(1):55-59.
27. Conio M., Filiberti R., Blanchi S., et al. Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 2002, 97(2):225-229.
28. Johansson J., Håkansson H.O., Mellblom L., et al. Risk factors for Barrett's oesophagus: a population-based approach. Scand J Gastroenterol 2007, 42(2):148-156.
29. Anderson L.A., Watson R.G., Murphy S.J., et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 2007, 13(10):1585.
30. de Jonge P.J., van Blankenstein M., Grady W.M., et al. Barrett's oesophagus: epidemiology, cancer risk and implications for management. Gut 2013, 63(1):191-202.
31. Bansal A., Wani S., Rastogi A., et al. Impact of measurement of esophageal acid exposure close to the gastroesophageal junction on diagnostic accuracy and event-symptom correlation: a prospective study using wireless dual pH monitoring. Am J Gastroenterol 2009, 104(12):2918-2925.
32. Lacy B.E., Chehade R., Crowell M.D. Aprospective study to compare a symptom-based reflux disease questionnaire to 48-h wireless pH monitoring for the identification of gastroesophageal reflux (revised 2-26-11). Am J Gastroenterol 2011, 106(9):1604-1611.
33. Avidan B., Sonnenberg A., Schnell T.G., et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002, 97(8):1930-1936.
34. Cameron A.J. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 1999, 94(8):2054-2059.
35. Eloubeidi M.A., Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. JClin Gastroenterol 2001, 33(4):306-309.
36. Taylor J.B., Rubenstein J.H. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. Am J Gastroenterol 2010, 105(8):1730-1737.
37. Brandt M.G., Darling G.E., Miller L. Symptoms, acid exposure and motility in patients with Barrett's esophagus. Can J Surg 2004, 47(1):47.
38. Singh P., Taylor R.H., Colin-Jones D.G. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present. Am J Gastroenterol 1994, 89(3):349-356.
39. El-Serag H.B., Aguirre T.V., Davis S., et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004, 99(10):1877-1883.
40. Wu A.H., Tseng C.C., Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 2003, 98(5):940-948.
41. Lagergren J. Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol 2011, 8(6):340-347.
42. Ogden C.L., Carroll M.D., Kit B.K., et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014, 311(8):806-814.
43. Kamat P., Wen S., Morris J., et al. Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis. Ann Thorac Surg 2009, 87(2):655-662.
44. Edelstein Z.R., Farrow D.C., Bronner M.P., et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007, 133(2):403-411.
45. Spechler S.J., Sharma P., Souza R.F., et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011, 140(3):e18.
46. Kubo A., Cook M.B., Shaheen N.J., et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut 2013, 62(12):1684-1691.
47. Obesity, inflammation and cancer 2013, Springer, New York (NY). N.A. Berger, A.J. Dannenberg (Eds.).
48. Kubo A., Levin T.R., Block G., et al. Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology 2009, 136(3):806-815.
49. Steevens J., Schouten L.J., Driessen A.L., et al. Aprospective cohort study on overweight, smoking, alcohol consumption, and risk of Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2011, 20(2):345-358.
50. Thrift A.P., Cook M.B., Vaughan T.L., et al. Alcohol and the risk of Barrett's esophagus: a pooled analysis from the International BEACON Consortium. Am J Gastroenterol 2014, 109(10):1586-1594.
51. Thrift A.P., Kramer J.R., Richardson P.A., et al. No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus. Dig Dis Sci 2014, 59(1):108-116.
52. Lepage C., Drouillard A., Jouve J.L., et al. Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis 2013, 45(8):625-629.
53. Cook M.B., Shaheen N.J., Anderson L.A., et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 2012, 142(4):744-753.
54. Stemmermann G.N. Intestinal metaplasia of the stomach. A status report. Cancer 1994, 74(2):556-564.
55. El-Serag H.B., Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998, 43(3):327-333.
56. Corley D.A., Kubo A., Levin T.R., et al. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut 2008, 57(6):727-733.
57. Chow W.H., Blaser M.J., Blot W.J., et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998, 58(4):588-590.
58. Vaezi M.F., Falk G.W., Peek R.M., et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 2000, 95(9):2206-2211.
59. Wang C., Yuan Y., Hunt R.H. Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis. Am J Gastroenterol 2009, 104(2):492-500.
60. Goldenberg R.L., Culhane J.F., Iams J.D., et al. Epidemiology and causes of preterm birth. Lancet 2008, 371(9606):75-84.
61. Forssell L., Cnattingius S., Bottai M., et al. Risk of esophagitis among individuals born preterm or small for gestational age. Clin Gastroenterol Hepatol 2012, 10(12):1369-1375.
62. Forssell L., Cnattingius S., Bottai M., et al. Increased risk of Barrett's esophagus among individuals born preterm or small for gestational age. Clin Gastroenterol Hepatol 2013, 11(7):790-794.
63. Forssell L., Cnattingius S., Bottai M., et al. Risk of oesophageal adenocarcinoma among individuals born preterm or small for gestational age. Eur J Cancer 2013, 49(9):2207-2213.
64. Leggett C.L., Gorospe E.C., Calvin A.D., et al. Obstructive sleep apnea is a risk factor for Barrett's esophagus. Clin Gastroenterol Hepatol 2014, 12(4):583-588.e1.
65. Garcia J.M., Splenser A.E., Kramer J., et al. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol 2014, 12(2):229-238.e3.
66. Bosch A., Frias Z., Caldwell W.L. Adenocarcinoma of the esophagus. Cancer 1979, 43(4):1557-1561.
67. Devesa S.S., Blot W.J., Fraumeni J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83(10):2049-2053.
68. American Cancer Society Cancer facts and figures 2014, American Cancer Society, Atlanta (GA).
69. Eloubeidi M.A., Mason A.C., Desmond R.A., et al. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?. Am J Gastroenterol 2003, 98(7):1627-1633.
70. Nordenstedt H., El-Serag H. The influence of age, sex, and race on the incidence of esophageal cancer in the United States (1992-2006). Scand J Gastroenterol 2011, 46(5):597-602.
71. Cook M., Chow W., Devesa S. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009, 101(5):855-859.
72. Hur C., Miller M., Kong C.Y., et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013, 119(6):1149-1158.
73. Younes M., Henson D.E., Ertan A., et al. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 2002, 37(12):1359-1365.
74. Pera M., Manterola C., Vidal O., et al. Epidemiology of esophageal adenocarcinoma. JSurg Oncol 2005, 92(3):151-159.
75. Reid B.J., Li X., Galipeau P.C., et al. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010, 10(2):87-101.
76. Brown L.M., Devesa S.S., Chow W.H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. JNatl Cancer Inst 2008, 100(16):1184-1187.
77. Vizcaino A.P., Moreno V., Lambert R., et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002, 99(6):860-868.
78. El-Serag H.B., Petersen N.J., Carter J., et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology 2004, 126(7):1692-1699.
79. Lagergren J., Nyrén O. Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a population-based cohort of prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1998, 7(10):913-915.
80. Kong C.Y., Kroep S., Curtius K., et al. Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer Epidemiol Biomarkers Prev 2013, 23:997-1006.
81. Thrift A.P., Whiteman D. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012, 23(12):3155-3162.
82. Lagergren J., Bergström R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. NEngl J Med 1999, 340(11):825-831.
83. Whiteman D.C., Sadeghi S., Pandeya N., et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008, 57(2):173-180.
84. Cook M.B., Corley D.A., Murray L.J., et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). PLoS one 2014, 9(7):e103508.
85. Ryan A.M., Duong M., Healy L., et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol 2011, 35(4):309-319.
86. Abrams J.A., Sharaiha R.Z., Gonsalves L., et al. Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007. Cancer Epidemiol Biomarkers Prev 2011, 20(1):183-186.
87. Chow W.H., Blot W.J., Vaughan T.L., et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. JNatl Cancer Inst 1998, 90(2):150-155.
88. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?. Gut 2005, 54(suppl 1):i1-i5.
89. Lagergren J., Bergström R., Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999, 130(11):883-890.
90. Hoyo C., Cook M.B., Kamangar F., et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol 2012, 41(6):1706-1718.
91. Abnet C.C., Freedman N.D., Hollenbeck A.R., et al. Aprospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer 2008, 44(3):465-471.
92. Steffen A., Schulze M.B., Pischon T., et al. Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2009, 18(7):2079-2089.
93. Singh S., Sharma A.N., Murad M.H., et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013, 11(11):1399-1412.e7.
94. Cook M.B., Kamangar F., Whiteman D.C., et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. JNatl Cancer Inst 2010, 102(17):1344-1353.
95. Lagergren J., Bergström R., Lindgren A., et al. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000, 85(3):340-346.
96. Anderson L.A., Cantwell M.M., Watson R.G., et al. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology 2009, 136(3):799-805.
97. Freedman N.D., Murray L.J., Kamangar F., et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut 2011, 60(8):1029-1037.
98. Parsonnet J., Friedman G.D., Vandersteen D.P., et al. Helicobacter pylori infection and the risk of gastric carcinoma. NEngl J Med 1991, 325(16):1127-1131.
99. Islami F., Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res 2008, 1(5):329-338.
100. Wu A.H., Crabtree J.E., Bernstein L., et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 2003, 103(6):815-821.
101. de Martel C., Llosa A.E., Farr S.M., et al. Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. JInfect Dis 2005, 191(5):761-767.
102. Engel L.S., Chow W.H., Vaughan T.L., et al. Population attributable risks of esophageal and gastric cancers. JNatl Cancer Inst 2003, 95(18):1404-1413.
103. Farrow D.C., Vaughan T.L., Hansten P.D., et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998, 7(2):97-102.
104. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124(1):47-56.
105. Sikkema M., Looman C.W., Steyerberg E.W., et al. Predictors for neoplastic progression in patients with Barrett's esophagus: a prospective cohort study. Am J Gastroenterol 2011, 106(7):1231-1238.
106. Nguyen D.M., Richardson P., El-Serag H.B. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010, 138(7):2260-2266.
107. Shaheen N.J., Crosby M.A., Bozymski E.M., et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 2000, 119(2):333-338.
108. Wani S., Falk G.W., Post J., et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 2011, 141(4):1179-1186.e1.
109. Reid B.J., Levine D.S., Longton G., et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low-and high-risk patient subsets. Am J Gastroenterol 2000, 95(7):1669-1676.
110. Levine D.S., Haggitt R.C., Blount P.L., et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993, 105:40-50.
111. Wang K.K., Sampliner R.E., Practice Parameters Committee of the American College of Gastroenterology Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008, 103(3):788-797.
112. Fitzgerald R.C., Saeed I.T., Khoo D., et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 2001, 46(9):1892-1898.
113. Abrams J.A., Kapel R.C., Lindberg G.M., et al. Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol 2009, 7(7):736.
114. Skacel M., Petras R.E., Gramlich T.L., et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000, 95(12):3383-3387.
115. Weston A.P., Banerjee S.K., Sharma P., et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001, 96(5):1355-1362.
116. Hameeteman W., Tytgat G.N., Houthoff H.J., et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989, 96(5 Pt 1):1249-1256.
117. Montgomery E., Goldblum J.R., Greenson J.K., et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001, 32(4):379-388.
118. Singh S., Manickam P., Amin A.V., et al. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 2014, 79(6):897-909.e4.
119. Reid B., Haggitt R.C., Rubin C.E., et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988, 19(2):166-178.
120. Meining A., Ott R., Becker I., et al. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only-what is the clinical significance?. Gut 2004, 53(10):1402-1407.
121. Sharma P., Falk G.W., Weston A., et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006, 4(5):566-572.
122. Gatenby P., Ramus J., Caygill C., et al. Routinely diagnosed low-grade dysplasia in Barrett's oesophagus: a population-based study of natural history. Histopathology 2009, 54(7):814-819.
123. de Jonge P.J., van Blankenstein M., Looman C.W., et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010, 59(8):1030-1036.
124. Gaddam S., Singh M., Balasubramanian G., et al. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology 2013, 145(3):548-553.e1.
125. Spechler S.J., Sharma P., Souza R.F., et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011, 140(3):1084-1091.
126. Fitzgerald R.C., di Pietro M., Ragunath K., et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014, 63(1):7-42.
127. Conio M., Blanchi S., Lapertosa G., et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003, 98(9):1931-1939.
128. Dulai G.S., Shekelle P.G., Jensen D.M., et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol 2005, 100(4):775-783.
129. Lim C., Treanor D., Dixon M.F., et al. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy 2007, 39(07):581-587.
130. Switzer-Taylor V., Schlup M., Lübcke R., et al. Barrett's esophagus: a retrospective analysis of 13 years surveillance. JGastroenterol Hepatol 2008, 23(9):1362-1367.
131. den Hoed C., van Blankenstein M., Dees J., et al. The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma. Br J Cancer 2011, 105(2):200-205.
132. Rugge M., Zaninotto G., Parente P., et al. Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). Ann Surg 2012, 256(5):788-795.
133. Picardo S., O'Brien M.P., Feighery R., et al. ABarrett's esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia. Dis Esophagus 2014, 28(2):121-126.
134. Schnell T.G., Sontag S.J., Chejfec G., et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001, 120(7):1607-1619.
135. Vieth M., Schubert B., Lang-Schwarz K., et al. Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study. Endoscopy 2006, 38(12):1201-1205.
136. Alcedo J., Ferrández A., Arenas J., et al. Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus 2009, 22(3):239-248.
137. Wong T., Tian J., Nagar A.B. Barrett's surveillance identifies patients with early esophageal adenocarcinoma. Am J Med 2010, 123(5):462-467.
138. Curvers W.L., ten Kate F.J., Krishnadath K.K., et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010, 105(7):1523-1530.
139. Jung K.W., Talley N.J., Romero Y., et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011, 106(8):1447-1455.
140. Schouten L.J., Steevens J., Huysentruyt C.J., et al. Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2011, 9(9):754-761.
141. Duits L.C., Phoa K.N., Curvers W.L., et al. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut 2014, [Epub ahead of print].
142. Thota P.N., Lee H.J., Goldblum J.R., et al. Risk stratification of patients with Barrett's esophagus and low-grade dysplasia or indefinite for dysplasia. Clin Gastroenterol Hepatol 2015, 13(3):459-465.e1.
143. Rastogi A., Puli S., El-Serag H.B., et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008, 67(3):394-398.
144. Wani S., Falk G., Hall M., et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011, 9(3):220-227.e1.
145. Weston A.P., Badr A.S., Hassanein R.S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999, 94(12):3413-3419.
146. Gatenby P.A., Caygill C.P., Ramus J.R., et al. Short segment columnar-lined oesophagus: an underestimated cancer risk? A large cohort study of the relationship between Barrett's columnar-lined oesophagus segment length and adenocarcinoma risk. Eur J Gastroenterol Hepatol 2007, 19(11):969-975.
147. Srivastava A., Hornick J.L., Li X., et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2007, 102(3):483-493.
148. Buttar N.S., Wang K.K., Sebo T.J., et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001, 120(7):1630-1639.
149. Dar M., Goldblum J.R., Rice T.W., et al. Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?. Gut 2003, 52(4):486-489.
150. Kastelein F., Biermann K., Steyerberg E.W., et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013, 62(12):1676-1683.
151. Reid B.J., Prevo L.J., Galipeau P.C., et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001, 96(10):2839-2848.
152. Allison R.K., Skipper H.E., Reid M.R., et al. Studies on the photosynthetic reaction. I. The assimilation of acetate by Nostoc muscorum. JBiol Chem 1953, 204(1):197-205.
153. Bird-Lieberman E.L., Dunn J.M., Coleman H.G., et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 2012, 143(4):927-935.e3.
154. Rabinovitch P.S., Longton G., Blount P.L., et al. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001, 96(11):3071-3083.
155. Timmer M., Sun G., Gorospe E.C., et al. Predictive biomarkers for Barrett's esophagus: so near and yet so far. Dis Esophagus 2013, 26(6):574-581.
156. Davelaar A.L., Calpe S., Lau L., et al. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: a prospective follow-up study. Genes Chromosomes Cancer 2015, 54(2):82-90.
157. Gerson L.B., Shetler K., Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002, 123(2):461-467.
158. Ward E.M., Wolfsen H.C., Achem S.R., et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 2006, 101(1):12-17.
159. Zou D., He J., Ma X., et al. Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis: the systematic investigation of gastrointestinal diseases in China (SILC). Scand J Gastroenterol 2011, 46(2):133-141.
160. Cook M., Wild C., Forman D. Asystematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol 2005, 162(11):1050-1061.
161. Corley D.A., Kubo A., Levin T.R., et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007, 133(1):34-41.
162. Abnet C., Freedman N.D., Kamangar F., et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009, 100(3):551-557.